President & Chief Executive Officer
Garth Cumberlidge has served as the Company’s President, Chief Executive Officer and member of the Board of Directors since September 2005. Dr. Cumberlidge has over 25 years experience in the research products, diagnostics and healthcare industries.
Prior to his joining Mimetogen, he was President & CEO of Qbiogene Inc., where over a period of six years he successfully raised over $50 million in venture funding and grew the company to over $50 million in revenues. Prior to that he held a senior executive position in ICN Pharmaceuticals, as Vice President, Worldwide Marketing & Sales for the ICN Biomedicals portfolio. Prior to that he held senior positions in Sigma Chemicals Company as European Sales & Marketing Manager, based in Munich, Germany, and Worldwide Sales & Marketing Manager based in the United States, with responsibility for the sales and marketing strategy for research immuno-chemicals business.
Dr. Cumberlidge holds a B.Sc. in Biochemistry and Genetics from the University of London (U.K.) and a PhD. in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin. (Germany)
Vice President Finance & Chief Financial Officer
François Mongrain has more than 20 years of financial experience centered on technology, growth-oriented businesses. During his 9 years in Entrepreneurial Services and Merger & Acquisition at Ernst & Young, he worked with several technology companies primarily active in the health care sector.
Following his Ernst & Young years, he became a founding partner of BridgeCapital Inc., a private consulting firm offering strategic and financial expertise to biotechnology companies. Through his years at E&Y and BridgeCapital, Mr. Mongrain played instrumental roles in more than 12 start-ups and participated in several IPO and private placements for young emerging companies.
Prior to Mimetogen, Mr. Mongrain co-founded Innodia, a biotech company focusing its R&D activity in developing novel drug for the treatment of diabetes and obesity. As Vice President Finance & CFO and then Chief Operating Officer, he successfully financed the Company’s research & development operations over a six-year period prior to orchestrating the sale of the Company to a publicly-listed Canadian biotechnology Company.
François received a Bachelor of Commerce degree from the Ecole des Hautes Etudes Commerciales (Montreal) and earned his Charted Accountant designation with Ernst & Young in 1993.See More »
Senior Director, Clinical Development
Karen Meerovitch has over 15 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry. At Mimetogen, Dr. Meerovitch started as the Company’s Senior Scientist and now serves as Senior Director, overseeing all non-clinical and clinical development activities of MIM-D3.
Prior to joining Mimetogen, she was Group Leader for all preclinical activities at Avance Pharma (Laval, Quebec). Prior to that she was Senior Scientist at Shire Biochem (Laval, Quebec), where she was a key contributor in the discovery and research of several projects in oncology drug discovery programs in the area of angiogenesis, apoptosis, and vascular targeting. Dr. Meerovitch has held appointments as Adjunct Professor at McGill University in the Department of Biochemistry and is currently in the Department of Pharmacology and Therapeutics. She is author or co-author of over 20 publications and reviews.
Dr. Meerovitch holds a B.Sc. and PhD. from McGill University and an M.Sc. from the University of Alberta, all in Biochemistry. She also completed a post-doctoral fellow in the Department of Medicine at McGill University.Go »